Parametric Portfolio Associates’s Rubius Therapeutics, Inc RUBY Stock Holding History

Parametric Portfolio Associates’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$289K	Buy	52,432 +70	+0.1%	+$445	﹤0.01%	3298
2021 Q4	$507K	Sell	52,362 -33,347	-39%	-$462K	﹤0.01%	3067
2021 Q3	$1.53M	Sell	85,709 -51,470	-38%	-$1.12M	﹤0.01%	2586
2021 Q2	$3.35M	Buy	137,179 +46,511	+51%	+$1.16M	﹤0.01%	2130
2021 Q1	$2.4M	Buy	90,668 +42,709	+89%	+$624K	﹤0.01%	2666
2020 Q4	$364K	Buy	47,959 +8,750	+22%	+$52K	﹤0.01%	3522
2020 Q3	$196K	Sell	39,209 -7,435	-16%	-$39.4K	﹤0.01%	3662
2020 Q2	$279K	Buy	46,644 +33,597	+258%	+$198K	﹤0.01%	3505
2020 Q1	$58K	Sell	13,047 -3,338	-20%	-$24.8K	﹤0.01%	3816
2019 Q4	$156K	Buy	+16,385	New	+$158K	﹤0.01%	3793

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $293M AUM 36.12% 1-Year Est. Return

Parametric Portfolio Associates's RUBY Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Rubius Therapeutics, Inc (RUBY) stake by 0.13% in Q1 2022, buying an estimated $445 and bringing the position to 52,432 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #3298.

Parametric Portfolio Associates first reported a position in RUBY in Q4 2019 and has held it in 10 quarters since. The position peaked at $3.35M in Q2 2021. 117 funds tracked by Wall St. Rank hold RUBY as of Q1 2022.

Parametric Portfolio Associates held 52,432 shares of Rubius Therapeutics, Inc worth $289K as of Q1 2022.
Parametric Portfolio Associates bought 70 Rubius Therapeutics, Inc shares in Q1 2022, an estimated $445.
Rubius Therapeutics, Inc made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3298 holding.
Parametric Portfolio Associates first reported a position in Rubius Therapeutics, Inc in Q4 2019 and has held it in 10 quarters since.
Parametric Portfolio Associates's Rubius Therapeutics, Inc position peaked at $3.35M in Q2 2021.
117 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.